ID   H9
AC   CVCL_1240
SY   HT clone H9; HT(H9); H 9; H-9
DR   BTO; BTO:0001944
DR   CLO; CLO_0003581
DR   CLO; CLO_0003612
DR   EFO; EFO_0003045
DR   CLDB; cl1556
DR   CLDB; cl1557
DR   CLDB; cl7167
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-176
DR   BioSample; SAMN03472731
DR   CCRID; 3142C0001000000031
DR   Cell_Model_Passport; SIDM01251
DR   ChEMBL-Cells; CHEMBL3308402
DR   ChEMBL-Targets; CHEMBL614806
DR   Cosmic; 687842
DR   Cosmic; 907043
DR   Cosmic; 933542
DR   Cosmic; 2301568
DR   Cosmic; 2668295
DR   Cosmic-CLP; 907043
DR   DepMap; ACH-002240
DR   ECACC; 85050301
DR   GDSC; 907043
DR   GEO; GSM1669836
DR   ICLC; HTL05006
DR   KCB; KCB 200418YJ
DR   KCLB; 30176
DR   Lonza; 910
DR   NIH-ARP; 87-436
DR   PharmacoDB; H9_439_2019
DR   TOKU-E; 3613
DR   Wikidata; Q54872230
RX   PubMed=1460674;
RX   PubMed=2193399;
RX   PubMed=2567177;
RX   PubMed=8127147;
RX   PubMed=8320746;
RX   PubMed=8641406;
RX   PubMed=17170727;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Characteristics: Permissive for HIV-1 replication. Is accordingly used to isolate and propagate HIV-1 from the blood of patients with AIDS.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: NRAS p.Gln61Lys (c.181C>A) (ClinVar=VCV000073058) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Arg196Ter (c.586C>T) (ClinVar=VCV000043589) (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=4.91%; Native American=1.41%; East Asian, North=5.59%; East Asian, South=0%; South Asian=0%; European, North=61.37%; European, South=26.72% (PubMed=30894373).
CC   Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177). This created a controversy between the labs of Minna and Gallo (PubMed=2193399).
CC   Discontinued: IZSLER; BS TCL 19; probable.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; Cosmic-CLP; ECACC; KCLB
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 8,12
ST   D16S539: 11,12
ST   D3S1358: 15,16
ST   D5S818: 11
ST   D7S820: 8,11
ST   FGA: 21,25
ST   TH01: 8,9
ST   TPOX: 8,9
ST   vWA: 14,15
DI   NCIt; C9265; Mycosis fungoides and Sezary syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0337 ! HuT 78
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 26
RX   PubMed=1460674; DOI=10.1093/jnci/84.24.1922;
RA   Chen T.-R.;
RT   "Karyotypic derivation of H9 cell line expressing human
RT   immunodeficiency virus susceptibility.";
RL   J. Natl. Cancer Inst. 84:1922-1926(1992).
RX   PubMed=2193399; DOI=10.1126/science.2193399;
RA   Rubinstein E.;
RT   "The untold story of HUT78.";
RL   Science 248:1499-1507(1990).
RX   PubMed=2567177; DOI=10.1089/aid.1989.5.253;
RA   Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y.A., Popovic M.,
RA   Read-Connole E., Gallo R.C., Gazdar A.F.;
RT   "Origin of the HIV-susceptible human CD4+ cell line H9.";
RL   AIDS Res. Hum. Retroviruses 5:253-255(1989).
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
RX   PubMed=8320746; DOI=10.1093/jnci/85.14.1168;
RA   Bunn P.A. Jr., Whang-Peng J., Gazdar A.F., Minna J.D., Carney D.N.;
RT   "Karyotypic derivation of H9 cell line.";
RL   J. Natl. Cancer Inst. 85:1168-1169(1993).
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., Macleod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).